BioPorto developing point-of-care test for SARS-CoV-2 on the proprietary gRAD platform

BioPorto A/S (CPH:BIOPOR) (FRA:2P4) has announced that it is developing a point-of-care test for SARS-CoV-2 on the proprietary gRAD platform, which is designed to quickly and easily identify infected patients using a non-invasive sample.  While indicative data from the process and studies in the US and Denmark support the gRAD platforms strong capabilities as a technology for rapid testing, BioPorto said it seeks to secure a high sensitivity of more than 80% to further strengthen the clinical and commercial potential of the technology, compared to other rapid tests.  READ: BioPorto says first-quarter revenue increased by 33% driven by strong sales of antibodies and its NGAL test “Over the last months, we have increased sensitivity in our gRAD-based SARS-CoV-2 samples and studies, especially from the data developed and collected in Aarhus (DK),” said Jan Kuhlmann Andersen, COO of BioPorto, in a statement. “However, we are not yet at our target of 80%. Therefore, we have decided to prolong the data collection and studies and to focus resources on the Danish study site, as we, over the coming months, continue the development of the COVID-19 test for new mutations of the SARS-CoV-2 virus.” Conditional upon continued access to patients with SARS-CoV-2, the company said it expects the data collection to be completed in the third quarter of 2021.  If the data continue to support BioPorto’s initial laboratory findings, the company as previously announced intends to undertake CE mark filing in Europe and possibly submit an Emergency Use Authorization request to the US Food and Drug Administration (FDA). Contact the author: patrick@proactiveinvestors.com Follow him on Twitter @PatrickMGraham